Login
$CCCC
$2.63 -$0.02 (0.75%) After hours

$CCCC SEC Filings

Filed On Filing
16 Nov 2026 SCHEDULE 13G/A
13 Nov 2026 Form 4
12 Nov 2026 144
05 Nov 2026 10-Q
05 Nov 2026 8-K: Results of Operations and Financial Condition

1 C4 Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights Cemsidomide Phase 2 MOMENTUM Trial On Track to Complete Enrollment in 1Q 2027 with Initial ORR Data Expected in 2H 2027 Enrollment Complete for...

02 Oct 2026 Form 4: Anderson Kenneth Carl, Director

Received 3,662 shares as a grant or award ($11.5K)

02 Oct 2026 Form 4: Grogan Donna Roy, Director

Received 4,618 shares as a grant or award ($14.5K)

25 Sep 2026 8-K: Regulation FD Disclosure; Other Events

Protein degraded. Disease targeted. Lives transformed. September 2026 Exhibit 99.2

21 Sep 2026 Form 4: Adams Kendra, Chief Financial Officer

Received 6,250 shares by exercise or conversion · Gave up 2,775 shares to cover exercise price or tax ($9.41K)

14 Aug 2026 SCHEDULE 13G/A
14 Aug 2026 144
14 Aug 2026 144
14 Aug 2026 SCHEDULE 13G/A
14 Aug 2026 SCHEDULE 13G/A
13 Aug 2026 144
12 Aug 2026 144
12 Aug 2026 SCHEDULE 13G/A
11 Aug 2026 10-Q
11 Aug 2026 8-K: Results of Operations and Financial Condition

Cemsidomide’s Ongoing Phase 2 MOMENTUM Trial and Phase 1b Trial in Combination With Elranatamab Remain on Track to Deliver Clinical Data Readouts in 2027

27 Jul 2026 SCHEDULE 13G

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support